Publique en esta revista
Información de la revista
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 50-55 (Marzo 2008)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 4. Núm. S1.
Monográfico: Enfermedades sistémicas autoinmunitarias
Páginas 50-55 (Marzo 2008)
Enfermedades sistémicas autoinmunitarias
Acceso a texto completo
Aspectos clínicos novedosos en la enfermedad de Behçet
New Clinical Aspects of Behçet's Disease
Visitas
...
Jenaro Graña Gil??
Autor para correspondencia
xenaro@mundo-r.com

Correspondencia: Dr. J. Graña Gil. Servicio de Reumatología. Complejo Hospitalario Universitario Juan Canalejo. Xubias de Arriba, 84. 15006 A Coruña. España.
Servicio de Reumatología. Complejo Hospitalario Universitario Juan Canalejo. A Coruña. España
Información del artículo
Resumen
Bibliografía
Descargar PDF
Estadísticas

La etiopatogenia del síndrome o enfermedad de Behçet (EB) sigue siendo esquiva y sus manifestaciones clínicas, muy complejas, y genera una buena cantidad de artículos científicos. Por ejemplo, una búsqueda simple en PubMed muestra que en los últimos 5 años se han publicado 1.394 artículos, 159 de ellos revisiones. Además de los estudios básicos sobre etiopatogenia y mecanismos de la enfermedad, las diversas manifestaciones clínicas y sus tratamientos, también es fuente de debate la propia definición de la enfermedad, su clasificación y los criterios de clasificación y diagnóstico. En este artículo revisamos algunos aspectos en debate, así como las últimas alternativas terapéuticas y la situación de la EB en España.

Palabras clave:
Enfermedad de Behçet
Síndrome de Adamantiades-Behçet
Revisión

Behçet's disease/syndrome (BD) continues being aloof in his etiopathogenesis and very complex in its clinical manifestations. BD generates a good amount of scientific articles. For example, a simple search in PubMed sample that in the last 5 years has been published 1394 articles, 159 of them revisions. In addition to the basic studies on etiopahtogenesis and disease mechanisms, the diverse clinical manifestations and their treatments, also the own definition of the disease, its classification and the criteria of classification and diagnosis are debate source. In this article we reviewed some aspects in discussin as well as the last therapeutic alternatives and the situation of the EB in Spain.

Key words:
Behçet's disease/syndrome
Adamantiades-Behçet's disease
Review
El Texto completo está disponible en PDF
Bibliografía
[1.]
A. Kalayciyan, C.C. Zouboulis.
An update on Behçet's disease.
[2.]
K.H. Lee, H.S. Chung, H.S. Kim, S.H. Oh, M.K. Ha, J.H. Baik, et al.
Human alpha-enolase from endothelial cells as a target antigen of anti-endothelial cell antibody in Behçet's disease.
Arthritis Rheum, 48 (2003), pp. 2025-2035
[3.]
J. Radons, G. Multhoff.
Immunostimulatory functions of membrane-bound and exported heat shock protein 70.
Exerc Immunol Rev, 11 (2005), pp. 17-33
[4.]
F. Pratesi, S. Moscato, A. Sabbatini, D. Chimenti, S. Bombardieri, P. Migliorini.
Autoantibodies specific for –enolase in systematic autoimmune disorders.
J Rheum, 27 (2000), pp. 109-115
[5.]
G.M. Verjans, P.M. van Hagen, A. van der Kooi, A.D. Osterhaus, G.S. Baarsma.
V 9V 2 T cells recovered from eyes of patients with Behçet's disease recognize non-peptide prenyl pyrophosphate antigens.
J Neuroimmunol, 130 (2002), pp. 46-54
[6.]
F.M. Spada, E.P. Grant, P.J. Peters, M. Sugita, A. Melián, D.S. Leslie, et al.
Self-recognition of CD1 by T cells: implications for innate immunity.
J Exp Med, 191 (2000), pp. 937
[7.]
N. Mizuki, M. Ota, M. Kimura, S. Ohno, H. Ando, Y. Katsuyama, et al.
Triplet repeat polymorphism in the transmembrane region of the MICA gene: a strong association of six GCT repetitions with Behçet disease.
Proc Natl Acad Sci USA, 94 (1997), pp. 1298-1303
[8.]
J. Katsantonis, Y. Adler, C.E. Orfanos, C.C. Zouboulis.
Adamantiades-Behçet's disease: serum IL-8 is a more reliable marker for disease activity than c-reactive protein and erythrocyte sedimentation rate.
Dermatology, 201 (2000), pp. 37-39
[9.]
B.E. Aken, M. den Heijer, G.M.J. Bos, S.J.H. van Deventer, P.H. Reitsma.
Recurrent venous thrombosis and markers of inflammation.
Thromb Haemost, 83 (2000), pp. 536-539
[10.]
F.J. Neumann, I. Ott, N. Marx, T. Luther, S. Kenngott, M. Gawaz, et al.
Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity.
Arterioscler Thromb Vasc Biol, 17 (1997), pp. 3399-3405
[11.]
H. Yazici, I. Fresko, S. Yurdakul.
Behçet's syndrome: disease manifestations, management, and advances in treatment.
Nature Clin Pract Rheumatol, 3 (2007), pp. 148-155
[12.]
J.T. Lie.
Vascular involvement in Behcet's disease: arterial and venous and vessels of all sizes.
J Rheumatol, 19 (1992), pp. 341-343
[13.]
G.E. Ehrlich.
Vasculitis in Behcet's disease.
Int Rev Immunol, 14 (1997), pp. 81-88
[14.]
I. Touitou, X. Magne, N. Molinari, A. Navarro, A. Le Quellec, P. Picco, et al.
MEFV mutations in Behçet's disease.
[15.]
P. Atagundunz, T. Ergun, H. Direskeneli.
MEFV mutations are increased in Behçet's disease (BD) and are associated with vascular involvement.
Clin Exp Rheumatol, 21 (2003), pp. S35-S37
[16.]
Z. Amoura, C. Dode, S. Hue, S. Caillat-Zucman, S. Bahram, M. Delpech, et al.
Association of the R92Q TNFRSF1A mutation and extracranial deep vein thrombosis in patients with Behcet's disease.
Arthritis Rheum, 52 (2005), pp. 608-611
[17.]
I. Kone-Paut, E. Sanchez, A. Le Quellec, R. Manna, I. Touitou.
Autoinflammatory gene mutations in Behçet's disease.
Ann Rheum Dis, 66 (2007), pp. 832-834
[18.]
G. Espinosa, J.I. Arostegui, S. Plaza, J. Rius, R. Cervera, J. Yague, et al.
Behcet's disease and hereditary periodic fever syndromes: casual association or causal relationship?.
Clin Exp Rheumatol, 23 (2005), pp. S64-S66
[19.]
H. Yazici, I. Fresko.
Behçet's disease and other autoinflammatory conditions: What's in a name?.
Clin Exp Rheumatol, 23 (2005), pp. S1-S2
[20.]
International Study Group for Behçet's Disease.
Criteria for the diagnosis of Behçet's disease.
Lancet, 335 (1990), pp. 1078-1080
[21.]
N. Pipitone, O. Olivieri, F. Cantini, G. Triolo, C. Salvarani.
New approaches in the treatment of Adamantiades-Behçet's disease.
Curr Op Rheumatol, 18 (2006), pp. 25-32
[22.]
S. Yurdakul.
Evidence-based treatment of Behçet's syndrome.
Clin Exp Rheumatol, 24 (2006), pp. S53-S55
[23.]
P.P. Sfikakis, N. Markomichelakis, E. Alpsoy, S. Assaad-Khalil, B. Bodaghi, A. Gul, et al.
Anti-TNF therapy in the management of Behçet's disease. Review and basis for recommendations.
Rheumatology, 46 (2007), pp. 736-741
[24.]
O. Kahraman.
Long-term course of deep venous trombosis in patients with Behçet's disease [resumen].
Arthritis Rheum, 48 (2003), pp. S385
[25.]
J.M. Ricart, J. Todoli, J.J. Vilata, J. Calvo, J. Roman, M. Santaolaria, et al.
Behcet disease: study of 74 patients.
Med Clin (Barc), 127 (2006), pp. 496-499
[26.]
J.M. Ricart, A. Vaya, J. Todoli, J. Calvo, P. Villa, A. Estelles, et al.
Thrombophilic risk factors and homocysteine levels in Behcet's disease in eastern Spain and their association with thrombotic events.
Thromb Haemost, 95 (2006), pp. 618-624
[27.]
J.M. Ricart, A. Vaya, M. Santaolaria, F. Espana, J. Aznar.
Dyslipidaemia in Behcet's disease as a thrombotic risk factor.
Ann Rheum Dis, 65 (2006), pp. 1248-1249
[28.]
J.M. Ricart, A. Vaya, J. Todoli, J. Calvo, M.T. Contreras, F. Espana, et al.
Haemorheological alterations in Behcet's disease are not related to a tendency for venous thrombosis.
Thromb Res, 115 (2005), pp. 399-404
[29.]
S. Navarro, J.M. Ricart, P. Medina, A. Vaya, P. Villa, J. Todoli, et al.
Activated protein C levels in Behcet's disease and risk of venous thrombosis.
Br J Haematol, 126 (2004), pp. 550-556
[30.]
M. Simo, J.M. Ricart, M. Santaolaria, G. Orti, A. Vaya.
Erythrocyte deformability does not seem to be altered in Behcet's disease.
Clin Hemorheol Microcirc, 36 (2007), pp. 83-88
[31.]
A. Vaya, J. Todoli, M.L. Santaolaria, J. Calvo, J. Aznar.
Erythrocyte aggregation in Behcet's disease determined with the Sefam and Myrenne aggregometer. Lack of association with thrombosis and uveitis.
Clin Hemorheol Microcirc, 33 (2005), pp. 389-396
[32.]
A. Vaya, J. Ricart, J. Todoli, L. Mico, T. Contreras, J. Aznar.
Do hemorheological alterations play any role in the development of thrombotic events in Behcet's disease?.
Clin Hemorheol Microcirc, 30 (2004), pp. 411-414
[33.]
I. Munoz-Saa, A. Cambra, L. Pallares, G. Espinosa, A. Juan, F. Pujalte, et al.
Allelic diversity and affinity variants of MICA are imbalanced in Spanish patients with Behcet's disease.
Scand J Immunol, 64 (2006), pp. 77-82
[34.]
G. Espinosa, J.I. Arostegui, S. Plaza, J. Rius, R. Cervera, J. Yague, et al.
Behcet's disease and hereditary periodic fever syndromes: casual association or causal relationship?.
Clin Exp Rheumatol, 23 (2005), pp. S64-S66
[35.]
J.A. Gomez-Puerta, G. Espinosa, J.M. Miro, O. Sued, J.M. Llibre, R. Cervera, et al.
Behcet's disease in an HIV-1-infected patient treated with highly active antiretroviral therapy.
Isr Med Assoc J, 8 (2006), pp. 513-514
[36.]
R. Penafiel Burkhardt, J.L. Callejas Rubio, J.F. Jimenez Alonso, N. Ortego Centeno.
Behcet's disease in Spain.
Med Clin (Barc), 128 (2007), pp. 717
[37.]
D. Sánchez-Cano, J.L. Callejas-Rubio, N. Ortego-Centeno, R. Ruiz-Villaverde.
Urticaria and angioedema in a patient with Behçet's disease treated with adalimumab.
Clin Exp Rheumatol, 24 (2006), pp. S128
[38.]
F.J. Sanjuan Portugal, R. Traspas Tejero, C. Llanos Chavarri, L.A. Sanchez Munoz, J. Castiella Herreros, J. Naya Manchado.
62 year old woman with orogenital apththosis, eye lesions and chondritis.
Rev Clin Esp, 206 (2006), pp. 528-530
[39.]
F.J. García Hernández, C. Ocana Medina, L. Mateos Romero, J. Sánchez Roman, D. García Solis, J.R. Franco-Baux, et al.
[Usefulness of brain SPECT with HMPAO-99mTc and psychological tests for diagnosis of neurological involvement in Behcet's disease].
Med Clin (Barc), 119 (2002), pp. 447-450
[40.]
M. Moraleda-Cibrian, M.A. Aracil-Martínez, G. Ercilla-González, J. Ros-Viladoms, V. Cusi-Sánchez, E. González-Pascual, et al.
[Early onset Neurobehcet's disease].
Rev Neurol, 42 (2006), pp. 150-152
[41.]
N. Caballol, A. Domínguez, A. Vidaller, S. Martínez-Yelamos.
[Endovascular treatment of carotid and pulmonary aneurysms in Behcet's disease].
Neurologia, 20 (2005), pp. 370-373
[42.]
O. García García, A. Vidaller Palacin, J. Muñoz Sánchez, G. Roca Linares.
[Granulocyteapheresis in ocular Behcet's disease resistant to medical treatment].
Arch Soc Esp Oftalmol, 79 (2004), pp. 335-340
[43.]
J. Moises, J.V. Torregrosa, J. Ybarra, F. Oppenheimer.
Renal transplantation in a CANCA(+) patient with Behçet disease and rapidly progressive glomerulonephritis.
Clin Nephrol, 61 (2004), pp. 357-359
[44.]
A. Vidaller Palacin, J. Robert Olalla, B. Sanuy Jiménez, G. Rufi Rigau, J. Folch Civit, A. Charte González.
[Behcet's disease therapy review].
An Med Interna, 19 (2002), pp. 594-598
[45.]
J.M. Benitez-del-Castillo, J.M. Martinez-de-la-Casa, E. Pato-Cour, R. Mendez-Fernandez, C. Lopez-Abad, M. Matilla, et al.
Long-term treatment of refractory posterior uveitis with anti-TNFalpha (infliximab).
[46.]
J.M. García-Pinilla, J. Pombo Jiménez, R. Carretero, E. González-Cocina.
Disfunción ventricular izquierda asociada a la enfermedad de Behçet.
Med Clin (Barc), 124 (2005), pp. 558-559
[47.]
M.J. Soleto, L. Marcos.
Behcet's disease involving the breast.
Eur Radiol, 12 (2002), pp. S98-S100
[48.]
A.M. García-Aparicio, M.A. Leal, M. Platero, P. Beneyto.
Enfermedad de Behçet en tratamiento con ciclosporina y crisis comiciales: el dilema diagnóstico.
Rev Clin Esp, 207 (2007), pp. 422-426
Copyright © 2008. Elsevier España S.L. Barcelona
Idiomas
Reumatología Clínica

Suscríbase a la newsletter

Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?